牛牛AI助理已提取核心訊息
Avenue Therapeutics, Inc. has announced that stockholders holding approximately 56% of the voting power have approved a reverse stock split of the company's issued and outstanding common stock. The range for the reverse stock split is set between 30-for-1 and 75-for-1, with the exact ratio to be determined by the board of directors. The board unanimously approved the proposal and recommended stockholder approval. The reverse stock split is subject to the board's discretion regarding the timing and necessity of the action. The Information Statement regarding this action was mailed to stockholders on or about a date in 2024, which has not been specified in the announcement. The effective date of the reverse stock split will be no earlier than a date in 2024, also not specified, following the board's determination. This action does not require a stockholder meeting or additional votes, as the written consent already satisfies Delaware law requirements for such corporate actions.
Avenue Therapeutics, Inc. has announced that stockholders holding approximately 56% of the voting power have approved a reverse stock split of the company's issued and outstanding common stock. The range for the reverse stock split is set between 30-for-1 and 75-for-1, with the exact ratio to be determined by the board of directors. The board unanimously approved the proposal and recommended stockholder approval. The reverse stock split is subject to the board's discretion regarding the timing and necessity of the action. The Information Statement regarding this action was mailed to stockholders on or about a date in 2024, which has not been specified in the announcement. The effective date of the reverse stock split will be no earlier than a date in 2024, also not specified, following the board's determination. This action does not require a stockholder meeting or additional votes, as the written consent already satisfies Delaware law requirements for such corporate actions.
Avenue Therapeutics, Inc.宣佈，持有約56％投票權的股東已批准對該公司已發行和流通的普通股進行反向股票分割。反向股票拆分的範圍設定在30比1和75比1之間，確切的比率將由董事會決定。董事會一致批准了該提案，並建議股東批准。反向股票拆分由董事會自行決定行動的時間和必要性。有關此行動的信息聲明是在2024年左右郵寄給股東的，公告中沒有具體說明。根據董事會的決定，反向股票拆分的生效日期將不早於2024年的日期，也未具體說明。該行動不需要股東大會或額外投票，因爲書面同意已經滿足了特拉華州法律對此類公司行爲的要求。
Avenue Therapeutics, Inc.宣佈，持有約56％投票權的股東已批准對該公司已發行和流通的普通股進行反向股票分割。反向股票拆分的範圍設定在30比1和75比1之間，確切的比率將由董事會決定。董事會一致批准了該提案，並建議股東批准。反向股票拆分由董事會自行決定行動的時間和必要性。有關此行動的信息聲明是在2024年左右郵寄給股東的，公告中沒有具體說明。根據董事會的決定，反向股票拆分的生效日期將不早於2024年的日期，也未具體說明。該行動不需要股東大會或額外投票，因爲書面同意已經滿足了特拉華州法律對此類公司行爲的要求。
有用
沒用